Decibel Therapeutics Added to Russell 2000 Index
March 22, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments...
Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
March 04, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
February 24, 2021 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data...
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
February 19, 2021 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Pricing of Initial Public Offering
February 11, 2021 21:51 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...